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Abstract 
Purpose: “Vespid Allergy Quality of Life Questionnaire (VQLQ)” has been used to assess psychological burden of 
disease. The aim of this study was to evaluate validity, reliability and responsiveness to interventions of the Turkish 
version.
Methods: The Turkish language Questionnaire (VQLQ-T) was administered to 81 patients with bee allergy and 65 
patients with vespid allergy from different groups to achieve cross-sectional validation. To establish longitudinal valid-
ity, the questionnaire was administered to 36 patients treated with venom immunotherapy.
Results: The cross-sectional validation in patients with vespid venom allergy showed a correlation coefficient of 
0.97 (Cronbach α). Spearman’s correlation coefficient of the pretreatment VQLQ-T score with Expectation of Outcome 
(EoO) questionnaire score was 0.55 (p < 0.001). After treatment, correlation between VQLQ-T score and EoO score 
was 0.64 (p = 0.003) in these patients. The cross-sectional instrument validation for non-beekeepers with bee venom 
allergy yielded a correlation coefficient of 0.96 (Cronbach α). Spearman’s correlation coefficient between pretreatment 
VQLQ-T score and EoO score was 0.47 (p < 0.001) and after treatment, correlation between VQLQ-T score and EoO 
score was 0.78 (p = 0.008) in these patients. These findings indicate cross-sectional validity of VQLQ-T. In the longi-
tudinal validation, there was a positive correlation between EoO and VQLQ-T with a correlation coefficient of 0.562 
(p < 0.001). While mean (±SD) VQLQ-T score was 5.27 (±1.29) in pretreatment, it was 2.78 (±1.01) after treatment 
(p < 0.001). The correlation between the mean change in VQLQ-T score and the mean change in EoO score was 0.42 
(p = 0.011).
Conclusions: The Turkish version of VQLQ-T enables measurement of Quality of Life (QoL) in patients with either 
vespid or bee venom allergy. Furthermore, responsiveness of this instrument demonstrates the questionnaire’s ability 
to detect changes over time.
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Background
In recent years, Quality of Life (QoL) issues have become 
an interesting topic in many diseases. Health-related 
quality-of-life (HRQoL) questionnaires are increasingly 
used in both research and patient care as they enable the 
evaluation of health status and treatment outcomes rel-
evant to the patient (Oude Elberink 2006). Several studies 
have shown that allergic diseases are frequently associ-
ated with a diminished QoL, which in turn also affects 
healthcare costs (Franzese and Burkhalter 2010; Teufel 
et  al. 2007). However, little is known about the Qual-
ity of Life of patients who are allergic to insect venom. 
Disease-specific questionnaires are preferred for specific 
allergic diseases and thought to be more sensitive than 
the generic ones (Baiardini et  al. 2003). Hymenoptera 
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venom allergy is one of the most important causes of life-
threatening allergic events. Different from the allergic 
diseases with ongoing symptoms, patients suffering from 
systemic sting reactions occasionally experience symp-
toms due to the unexpected venom exposure. However, 
this special group of patients may still be found to have 
an impaired QoL due to venom allergy as a result of their 
efforts to prevent accidental exposures (Oude Elberink 
et al. 2002a).
The intensity of systemic reaction to insect stings 
ranges between mild cutaneous and severe allergic mani-
festations, with anaphylactic shock even leading to death 
in some cases. Due to the characteristic nature of the 
disease, the impact of insect venom allergy on HRQoL 
may be associated with several social restrictions and 
limitation of daily activities for subjects. In recent years, 
although QoL and the psychological burden of disease in 
special patient groups such as food and drug allergy are 
increasingly important topics in medical care and clini-
cal research, there is limited knowledge about the QoL of 
patients with venom allergy (Oude Elberink 2006; Teufel 
et al. 2007; Gowland 2002; Antolin-Amerigo et al. 2015; 
Baiardini et al. 2015). This may be due to the methodo-
logical difficulties in developing a questionnaire survey. 
Measurement of HRQoL in patients with venom allergy 
was first proposed by Confino-Cohen et al. (1999). They 
used a non-standardized questionnaire, and showed that 
approximately one-third of patients receiving venom 
immunotherapy (VIT) perceived a moderate to severe 
impairment in their QoL and manifested symptoms of 
emotional distress despite ongoing therapy (Confino-
Cohen et  al. 1999). Later on in 2002, Oude Elberink 
et  al. developed and validated the first disease-specific 
instrument called ‘Vespid Allergy Quality of Life Ques-
tionnaire’ (VQLQ) to measure HRQoL in patients with 
anaphylaxis due to Vespula venom (Oude Elberink et al. 
2002a). To date, this tool has not been used to assess the 
validity and reliability of VQLQ scores in patients with 
bee venom allergy.
The prevalence of systemic reactions due to Hymenop-
tera stings in the general adult population was reported 
as between 1.2 and 4.3  % in Turkey, which was in line 
with representative studies from Europe and US (Gelin-
cik et  al. 2015; Tankersley and Ledford 2015). However, 
the Quality of Life scores of patients with venom allergy 
and especially in those receiving VIT has not yet been 
evaluated in Turkey. Therefore, in the present study we 
aimed to assess the validity and reliability of the Turk-
ish version of the VQLQ both cross-sectionally and lon-
gitudinally in adults with venom allergy. The secondary 
objectives were to evaluate the VQLQ use in patients 
with bee venom allergy and responsiveness of the tool to 
intervention in patients treated with VIT.
Methods
Patient selection
Four centers from Turkey participated in the study 
between the years 2010 and 2013. A total of 189 adult 
patients [103 M, 86 F mean age: 41.17  ±  12.26 years, 
median (min–max): 42 (17–70)] who had a history of sys-
temic sting reactions (SSRs) were screened for the study 
in the Allergy Outpatient Departments of these centers. 
Venom allergy to Vespula and/or Apis species was con-
firmed by positive skin test response and/or elevated 
titers of serum specific IgE antibodies (Bilo et al. 2005). 
Severity of the reactions ranged from mild to severe, 
which was graded according to the method of Mueller 
(Mueller 1966).
Specific IgE measurements/sensitization
Skin tests were performed with standardized pure venom 
extracts of Vespula vulgaris and Apis mellifera (ALK-
Abello, Madrid, Spain). Skin prick tests were applied 
by using 100 and 300  μg/ml concentrations. Histamine 
dihydrochloride (10  mg/ml) and glycerol diluent were 
used as positive and negative controls, respectively. A 
wheal diameter with erythema of 3 mm or greater than 
histamine, was accepted as a positive reaction. If the 
prick test result was negative, intradermal tests with the 
standard extracts of the same venom allergens (ALK-
Abello, Spain) were performed in tenfold increasing con-
centrations from 0.0001  µg/ml to a maximum of 1  µg/
ml of 0.02 ml of venom. Intradermal test response with 
a histamine equivalent wheal size of at least 5  mm at a 
concentration of less than 1 μg/ml was considered to be a 
positive reaction. Histamine and physiological saline with 
0.4 % phenol were used as positive and negative controls, 
respectively. The skin test results were read after 15 min. 
Patients were diagnosed as sensitized to Vespula vulgaris 
and/or Apis mellifera venoms. In all patients, specific IgE 
antibodies to Vespula vulgaris and Apis mellifera venoms 
were determined by using a florescence-immunoassay 
(Pharmacia CAP, Uppsala, Sweden). Antibody values of 
0.35 kU/L or more were classified in the range of class 1 
and class 6. Specific IgE result of at least class 2 was con-
sidered positive.
Instruments
We used the Turkish version of the Vespid Allergy Qual-
ity of Life Questionnaire (VQLQ-T) which was previ-
ously developed and validated in 2002 by Oude Elberink 
JNG with her permission (Oude Elberink et al. 2002a).
Translation and backtranslation of the English version
In order to use the Vespid Allergy Quality of Life Ques-
tionnaire (VQLQ) in Turkish, the VQLQ was first for-
ward translated into Turkish by a person who speaks 
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both English and Turkish. Then, it was independently 
backward translated from Turkish into English by 
another person in order to evaluate the accuracy of the 
translation. The translation was carried out without any 
changes by two academic staff at the Department of 
Western Languages and Literatures in the Faculty of Lan-
guages, History and Geography at the Ankara University 
(Zeynep Atayurt-Fenge and Devrim Kılıcer). In this way, 
the final version of the questionnaire-The Turkish Lan-
guage Questionnaire (VQLQ-T) was agreed upon by the 
authors of the original version, and the validation process 
was begun.
The original questionnaire consisted of 14 questions 
with 7 response options giving a score of 1–7, with lower 
scores representing higher QoL. In addition, there were 
two questions asking the patient about the likelihood of a 
severe allergic reaction or even death after being re-stung 
by a vespid or bee. The answers to these questions were 
used for validation of the previous 14 questions. The first 
six questions of this survey were related to anxiety symp-
toms in various forms (agitation) and avoidance and fear 
behavior (running away, avoiding certain places, need 
to have control). The other eight questions were related 
to stress due to increased vigilance. These are posed for 
general situations (e.g. being outdoors) as well as spe-
cific everyday situations (at work, while eating outside, 
gardening, being in nature or on vacation). Most of the 
questions were related to the emotional aspects of the 
patient’s life, although questions related to work, leisure, 
and outside activities were also included (Oude Elberink 
et al. 2002a).
The VQLQ-T, consisting of 14 items along with the 
Expectation of Outcome (EoO) questions (2 items), was 
administered to patients to achieve cross-sectional vali-
dation of the Turkish version. The EoO questionnaire was 
required to use as an external reference point for the vali-
dation. This had previously been used in the validation 
process of the original version, and consisted of 2 ques-
tions related to the risk perceived by patients of experi-
encing a severe allergic reaction or dying as a result of a 
new hymenoptera sting (Oude Elberink et al. 2002a).
In order to evaluate the validity of VQLQ-T for patients 
with bee venom allergy, the questionnaire was also 
applied to patients to identify issues in their daily lives 
affected by their allergy to honey bees.
Longitudinal validation of the questionnaire
A total of 36 patients [19 M/17 F, mean age: 46.25 ± 9.32 
years, median (min–max): 46.5 (28–69)] were included 
in the longitudinal validation. The VQLQ-T and the EoO 
Questionnaires were applied to patients prior to the deci-
sion of treatment modality. Consequently, in 27 patients 
who were sensitized to only bee or vespid venom and in 
9 patients who were both sensitized to vespid and bee 
venom, the measures were administered before VIT. 
After 3  years of treatment, the set of measures was re-
administered to establish longitudinal validity in these 
patients. The longitudinal item-based validation were 
examined over 36 patients (overall) and 27 patients (only 
with bee or vespid venom allergy).
Cross‑sectional validation of the questionnaire
Patients referred to the out-patient allergy departments 
because of a systemic allergic reaction after a vespid and/
or honey bee sting were asked to complete the VQLQ-T 
along with the EoO questions. For the cross-sectional val-
idation, we included patients aged over 17 years who were 
confirmed to be sensitized with the culprit insect after a 
systemic allergic reaction to venom from Vespula or Apis 
species. This questionnaire (VQLQ-T) was administered 
to 81 patients with bee venom allergy and 65 patients 
with vespid venom allergy. Forty-three patients demon-
strated double sensitization. Those patients who were 
sensitive to both venoms were excluded from the analy-
sis in order to avoid the misinterpretation of the data of 
patients with only bee or vespid venom allergy.
Patients were separated into four different groups 
depending on their current status. The first group (1) 
consisted of patients who were recently diagnosed 
(n  =  56), the second group (2) had patients who have 
recently started VIT but have not yet completed up-dos-
ing (n =  64). Patients in the maintenance phase of VIT 
formed the third group (3) (n = 48) and finally patients 
who had completed the VIT were in the fourth group (4) 
(n = 21) (Table 1). We applied VQLQ-T questionnaire to 
these groups at the same time point.
All of the patients, who participated in the study, gave 
their written informed consent. This study was approved 
by the Medical Ethics Committee of the Ankara Univer-
sity, Ankara, Turkey. All procedures performed in this 
study were in accordance with the ethical standards of 
the institutional research committee and with the 1964 
Helsinki declaration and its later amendments or compa-
rable ethical standards.
Statistical analysis
Statistical analyses were performed using SPSS 11.5. 
Mean  ±  standard deviation [median (minimum–maxi-
mum)] for metric variables, and frequency (percent) for 
categorical variables were given as descriptive statis-
tics. In order to compare independent groups in terms 
of metric variables, the Mann–Whitney U test was used 
for two groups, while the Kruskal–Wallis variance analy-
sis was used when more than two groups were involved. 
Paired samples t test was performed to compare the two 
dependent groups for metric variables. The Pearson/
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Spearman correlation coefficient was calculated to deter-
mine the association between variables, and p < 0.05 was 
considered statistically significant.
Scale (VQLQ‑T) reliability
Reliability was tested by Cronbach’s alpha coefficient 
(Cronbach 1951). Usually a reliability of 0.70 is required 
for analysis at group level, and values of 0.85 and higher 
for individual use (Streiner and Norman 1995).
Scale (VQLQ–T) validity
Cross-sectional validity (as internally) of the VQLQ-T 
was tested with item-scale correlations. Also, the corre-
lation between the VQLQ-T and the EoO (for pre treat-
ment and after treatment) was given at both the item and 
scale levels in terms of external validation. For longitu-
dinal validation (responsiveness), the paired t test was 
used for internal responsiveness, correlation between the 




Patients filled out the questionnaire in approximately 
10–15  min without requiring any assistance. The distri-
bution of venom sensitizations were honey bee in 81 sub-
jects (42.8 %), vespid in 65 patients (34.5 %), and a double 
sensitization both to honey bee and vespid was observed 
in 43 patients (22.7  %). There was no difference in the 
VQLQ-T scores in terms of the type of insect venom 
responsible for sensitization (Kruskal–Wallis Chi square 
test statistic = 0.669; p = 0.880).
All patients had experienced a systemic reaction after 
a vespid and/or a bee sting. The severity of reactions was 
graded according to the method of Mueller (1): Grade 
I: n = 21 (11.1 %), Grade II: n = 56 (29.6 %), Grade III: 
n = 55 (29.1 %), Grade IV: n = 57 (30.2 %).
A positive correlation between the degree of severity of 
the systemic reaction and the VQLQ-T scores (correla-
tion coefficient r = 0.041) was found, but it did not reach 
statistical significance (p =  0.578,  >  0.05). Furthermore, 
the degree of systemic reaction severity was significantly 
correlated with the skin test reactivity to vespula venom 
(r = 0.408, p = 0.025) and wheal diameter of histamine 
(r = 0.317, p < 0.001).
The mean duration of VIT was 4.5 ± 1.5 years for Apis 
mellifera, and it was 5.0 ± 0.1 years for Vespula vulgaris 
venom. There was a statistically significant difference in 
VQLQ scores between the recently started VIT group 
(mean  ±  SD: 5.03  ±  1.45 median: 5.4  min–max: 1.38–
7.00) and the group who had completed VIT (mean ± SD: 
4.35  ±  1.29 median: 4.3  min–max: 1.93–6.31) (Mann–
Whitney U test statistic = 812,500; p = 0.028). The mean 
VQLQ score was significantly lower in patients whose 
VIT had stopped. Furthermore, the VQLQ-T scores were 
inversely correlated with the duration of VIT (correlation 
coefficient: −0.267, p = 0.378).
Longitudinal instrument validation (responsiveness)
Longitudinal validity was studied in 36 patients as pre-
viously mentioned. After 3  years, the questionnaire was 
re-administered to patients treated with VIT. There was 
a positive correlation between the pretreatment EoO and 
the VQLQ-T with a correlation coefficient of 0.562, and 
this coefficient was statistically significant (p  <  0.001). 
While the mean (±SD) VQLQ-T score was 5.27 (±1.29) 
in pretreatment, it was 2.78 (±1.01) after treatment 
(p < 0.001). This finding supports the internal responsive-
ness of the VQLQ-T. The correlation between the mean 
change in the VQLQ-T score (mean ± SD: 2.48 ± 1.23) 
and the mean change in the EoO score (mean  ±  SD: 
3.15  ±  1.8) was 0.42 (p  =  0.011) indicating the exter-
nal longitudinal construct validity of the VQLQ-T. The 
results of longitudinal item-based validation over 36 
patients (overall) and 27 patients (only with bee or vespid 
venom allergy) are given in Tables 2 and 3, respectively.
Cross‑sectional validation of individual items in vespid 
venom allergy (n = 65)
For the cross-sectional validity; characteristics of patients 
with vespid and bee venom allergy depending on differ-
ent groups are shown in Table 1.
Table 1 Characteristics of  patients with  vespid or bee 
venom allergy
For the variables with *, cells represent mean ± standard deviation [median 




Age (years)* 42.33 ± 12.58 39.2 ± 13.06
[46 (18–70)] [38 (17–70)]
Gender
 Female, no (%) 34 (42 %) 33 (51 %)
 Male, no (%) 47 (58 %) 32 (49 %)
Severity of systemic reactions (%)
 Grade I 9 (11.1) 5 (7.7)
 Grade II 21 (26) 25 (38.5)
 Grade III 24 (29.6) 15 (23)
 Grade IV 27 (33.3) 20 (30.8)
Patient groups for cross-sectional validation
 New diagnosis 18 (22.2) 23(35.4)
 Recently started (up-dosing) VIT 30 (37) 18 (27.7)
 Receiving on maintenance VIT 22 (27.2) 16 (24.6)
 Stopped VIT 11 (13.6) 8 (12.3)
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The VQLQ-T consists of 14 items with inter-item cor-
relation coefficients ranging between 0.53 and 0.97. The 
Cronbach α of the 14 items was 0.97. The Spearman’s 
correlation coefficients between the individual items, the 
mean of all items and the EoO questionnaire are given in 
Table  4. The Spearman’s correlation coefficient between 
the pretreatment VQLQ-T score (mean ± SD: 4.7 ± 1.58) 
and EoO questionnaire score (mean ± SD: 5.23 ± 1.41) 
was 0.55 (p  <  0.001). After treatment, the correlation 
between the VQLQ score (mean  ±  SD: 2.81  ±  1.07) 
and the EoO score (mean  ±  SD: 2.8  ±  1.53) was 0.64 
(p  <  0.003). These findings indicate the cross-sectional 
validity of the VQLQ-T.
Longitudinal instrument validation in vespid venom 
allergy (n = 11)
The pretreatment mean (±SD) VQLQ-T score was 
5.27 (±1.41), while it was 2.5 (±1.08) after treatment 
(p < 0.001). This finding supports the internal responsive-
ness of the VQLQ-T. The correlation between the mean 
change in the VQLQ-T score (mean ±  SD: 2.41 ±  1.0) 
and the mean change in the EoO score (mean  ±  SD: 
2.50 ± 2.21) was 0.67 (p = 0.050), indicating the external 
longitudinal construct validity of the VQLQ-T.
Cross‑sectional validation of individual items in bee venom 
allergy (n = 81)
The VQLQ-T revealed correlation coefficients which 
were ranging between 0.48 and 0.90 for patients with bee 
venom allergy. The cross-sectional instrument validation 
yielded a correlation coefficient of 0.96 (Cronbach α). The 
Spearman correlation coefficients between the individual 
items and the mean of all items and the EoO question-
naire are shown in Table  5. The Spearman’s correlation 
coefficient between the pretreatment VQLQ-T score 
(mean ± SD: 4.9 ± 1.45) and the EoO score (mean ± SD: 
5.19  ±  1.39) was 0.49 (p  <  0.001). After treatment, the 
correlation between the VQLQ-T score (mean  ±  SD: 
2.76 ± 0.98) and the EoO score (mean ± SD: 2.56 ± 0.91) 
was 0.75 (p =  0.001). These findings indicate cross-sec-
tional validity of the VQLQ-T for bee venom allergy.
Longitudinal instrument validation in bee venom allergy 
(n = 16)
While the mean (±SD) VQLQ score was 5.07 (±1.36) 
in pretreatment, it was 2.76 (±0.98) after treatment 
(p < 0.001). This finding supports the internal responsive-
ness of the VQLQ-T. The correlation between the mean 
change in the VQLQ-T score (mean ± SD: 2.32 ± 1.13) 
and the mean change in the EoO score (mean  ±  SD: 
2.81 ± 1.83) was 0.55 (p = 0.029) indicating the external 
longitudinal construct validity of the VQLQ-T for bee 
venom allergy.
Among patients with bee venom allergy, there were 
28 (34.6  %) subjects who were doing beekeeping, while 
53 (65.4  %) patients were non-beekeepers. When we 
analyzed their VQLQ-T scores, there was a statistically 
significant difference between beekeepers and non-bee-
keepers (p < 0.05). The mean VQLQ score was lower for 
beekeepers than non-beekeepers (4.4 ± 1.5 vs. 5.1 ± 1.3). 
When the beekeepers were excluded from the analysis, 
remaining 53 cases consisted of non-beekeepers. In this 
group; the correlation coefficients were ranging between 
0.55 and 0.94. The Cronbach α of the 14 items was 0.96 
in the cross-sectional validation of individual items. The 
Table 2 Longitudinal item-based validation of the Turkish 
VQLQ and EoO (n = 36)
VQLQ 1–14 (Vespid allergy quality of life questionnaire), EoO Expectation of 
Outcome questionnaire (questions 1 and 2) (independent measure)
Before After Difference p value
VQLQ
VQLQ-1 5.58 ± 1.51  
[6 (1–7)]
3.05 ± 1.68  
[3 (1–7)]
2.53 ± 1.59 <0.001
VQLQ-2 5.11 ± 1.66 
[6 (2–7)]
2.61 ± 1.59  
[3 (1–7)]
2.5 ± 1.73 <0.001
VQLQ-3 5.86 ± 1.41  
[6 (2–7)]
3.52 ± 1.61  
[3 (1–7)]
2.33 ± 1.62 <0.001
VQLQ-4 5.08 ± 1.82  
[6 (1–7)]
2.72 ± 1.52  
[3 (1–7)]
2.36 ± 1.74 <0.001
VQLQ-5 5.14 ± 1.79  
[6 (2–7)]
2.97 ± 1.66  
[3 (1–7)]
2.17 ± 1.95 <0.001
VQLQ-6 4.94 ± 2.12  
[6 (1–7)]
2.88 ± 1.51  
[3 (1–7)]
2.06 ± 1.80 <0.001
VQLQ-7 4.65 ± 2.08  
[5 (1–7)]
2.22 ± 1.37  
[2 (1–7)]
2.43 ± 1.93 <0.001
VQLQ-8 5.37 ± 1.66  
[6 (1–7)]
2.74 ± 1.31  
[3 (1–5)]
2.63 ± 1.77 <0.001
VQLQ-9 5.63 ± 1.23  
[6 (3–7)]
2.86 ± 1.49  
[3 (1–7)]
2.77 ± 1.68 <0.001
VQLQ-10 5.18 ± 1.65  
[6 (1–7)]
2.77 ± 1.47  
[3 (1–7)]
2.41 ± 1.68 <0.001
VQLQ-11 5.22 ± 1.62  
[5 (1–7)]
2.56 ± 1.08  
[3 (1–5)]
2.65 ± 1.58 <0.001
VQLQ-12 5.55 ± 1.63  
[6 (2–7)]
2.95 ± 1.50  
[2.5 (1–6)]
2.6 ± 1.47 <0.001
VQLQ-13 5.09 ± 1.59  
[6 (2–7)]
2.75 ± 1.34  
[3 (1–6)]
2.34 ± 1.56 <0.001
VQLQ-14 5.74 ± 1.37  
[6 (2–7)]
2.80 ± 1.32  
[3 (1–6)]
2.94 ± 1.55 <0.001
EoO
EoO-1 5.83 ± 1.18  
[6 (2–7)]
2.58 ± 1.31  
[2 (1–7)]
3.25 ± 1.78 <0.001
EoO-2 5.97 ± 1.14  
[6 (3–7)]
2.73 ± 1.42  
[3 (1–7)]
3.24 ± 1.94 <0.001
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Spearman’s correlation coefficient between pretreatment 
VQLQ-T score (mean ± SD: 5.12 ± 1.34) and EoO ques-
tionnaire (mean ± SD: 5.06 ± 1.26) was 0.47 (p = 0.001). 
After treatment, correlation between the VQLQ-T score 
(mean ± SD: 2.8 ± 0.74) and the EoO score (mean ± SD: 
2.65 ±  1.11) was 0.78 (p =  0.008). These findings indi-
cate cross-sectional validity of the VQLQ-T. Longitudinal 
instrument validation in non-beekeepers demonstrated 
that the mean (±SD) VQLQ-T score was 4.84 (±1.33) in 
pretreatment whereas it was 2.8 (±0.74) after treatment 
(p < 0.001). This finding supports the internal responsive-
ness of the VQLQ-T. The correlation between the mean 
change in VQLQ-T score (mean ±  SD: 2.04 ±  1.2) and 
the mean change in EoO score (mean ± SD: 2.35 ± 1.84) 
was 0.28 (p  =  0.431). However, these findings are not 
enough to show the external longitudinal construct valid-
ity of VQLQ-T. The Spearman correlation coefficients 
between the individual items and the mean of all items 
and the EoO questionnaire were shown in Table 6.
Discussion
The present study showed that the Turkish version of 
VQLQ is a reliable and valid instrument for evaluating 
QoL in patients with insect venom allergy. The existing 
original English-language survey on vespid allergy QoL 
questionnaire was translated and backtranslated into 
Turkish language (VQLQ-T) based on current guidelines, 
and subsequently validated both cross-sectionally and 
longitudinally in either patients with vespid or bee venom 
allergy. Furthermore, this study was the first study which 
used the same instrument to measure QoL of patients 
with bee venom allergy.
In our study, there was a high level of internal consist-
ency and agreement with the original version. The cross-
sectional validity was established for the Turkish version 




Number of items Expectation of outcome
Q1 Q2 Mean of Q1 and Q2
Q1 0.466*** 0.443*** 0.494***
Q2 0.477*** 0.494*** 0.522***
Q3 0.469*** 0.332** 0.435***
Q4 0.291* 0.273* 0.301*
Q5 0.455*** 0.309* 0.389**
Q6 0.515*** 0.240* 0.408**
Q7 0.394** 0.520*** 0.501***
Q8 0.423** 0.372** 0.415**
Q9 0.567*** 0.434*** 0.535***
Q10 0.370* 0.351* 0.412**
Q11 0.567*** 0.546*** 0.611***
Q12 0.459* 0.214* 0.350*
Q13 0.428** 0.453** 0.480***
Q14 0.566*** 0.354** 0.501***
Mean (Q1–14) 0.536*** 0.469*** 0.549***




Number of items Expectation of Outcome
Q1 Q2 Mean of Q1 and Q2
Q1 0.506*** 0.328** 0.437***
Q2 0.404*** 0.260* 0.334**
Q3 0.503*** 0.323** 0.423***
Q4 0.266* 0.247* 0.276*
Q5 0.357** 0.325** 0.362**
Q6 0.318** 0.236* 0.277*
Q7 0.471*** 0.387*** 0.447***
Q8 0.534*** 0.412*** 0.495***
Q9 0.508*** 0.355** 0.450***
Q10 0.392** 0.289* 0.331*
Q11 0.340* 0.242* 0.321*
Q12 0.473*** 0.409** 0.447**
Q13 0.369** 0.338** 0.365**
Q14 0.559*** 0.377** 0.481***
Mean (Q1–14) 0.533*** 0.414*** 0.490***
Table 6 External validity of  the Turkish VQLQ in  non-bee-




VQLQ items Q1 Q2 Mean of Q1 and Q2
Q1 0.479*** 0.307* 0.431**
Q2 0.316* 0.182 0.249
Q3 0.411** 0.104 0.248
Q4 0.144 0.282* 0.255
Q5 0.343* 0.290* 0.345*
Q6 0.304* 0.195 0.239
Q7 0.454** 0.473*** 0.512***
Q8 0.420** 0.398** 0.448**
Q9 0.431** 0.298* 0.397**
Q10 0.342* 0.287 0.296
Q11 0.300 0.306 0.372*
Q12 0.460* 0.481** 0.509**
Q13 0.425** 0.397** 0.431**
Q14 0.491*** 0.313* 0.419**
Mean (Q1–14) 0.473*** 0.404** 0.465**
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by correlating responses to the items with the Expecta-
tion of Outcome questionnaire. We also showed high 
internal consistency by comparing the inter-item cor-
relation by means of the Cronbach α. Also, we attribute 
the high reliability (internal consistency) of the Turkish 
language version by using the method of translation/back 
translation. A comparison of the Pearson’s correlation 
coefficients of results of the surveys of the Turkish and 
English samples shows a good level of agreement. Addi-
tionally, the tool appeared to be responsive to interven-
tions including venom immunotherapy.
HRQoL is often measured as a patient-reported out-
come and is incorporated into clinical trials as an out-
come measurement beyond morbidity and mortality (US 
Food and Drug Administration (FDA)). However, the use 
of the validated disease specific HRQoL tools are rec-
ommended for different allergies such as drug, food or 
insect venom hypersensitivity (Bertine et al. 2008; Baiar-
dini et  al. 2011; Bavbek et  al. 2015; Oude Elberink and 
Dubois 2003). After the development and validation of 
the first disease-specific “Vespid Allergy Quality of Life 
Questionnaire (VQLQ)” in 2002, the validity, reliability, 
and sensitivity of this questionnaire has been shown in 
several studies. In agreement with our findings, valida-
tion of the German (VQLQ-d) and Spanish versions for 
adult patients, and Polish version for adolescents were 
also reported in addition to Dutch and English versions 
(Oude Elberink et al. 2002a; Fisher et al. 2011; Cichocka-
Jarosz et al. 2012; Armisen et al. 2015). Cichocka-Jarosz 
et al. developed a new scale for children and adolescents 
measuring six dimensions of HRQoL related to Hyme-
noptera venom allergy, and demonstrated high validity 
and reliability (Cichocka-Jarosz et  al. 2013). This sug-
gests that this instrument is suitable for adaptation to the 
different cultural settings from a HRQoL point of view. 
Until now, no adapted or original scale to measure the 
QoL in venom allergic patients has been used in Tur-
key. Our study is the first one that adapted the VQLQ 
to the Turkish population. Furthermore, the reliability 
and validity of Turkish version of VQLQ-T were evalu-
ated both in patients with vespid and bee venom allergy. 
Consistent with results from other authors, the statisti-
cal analyses provided evidence that the Turkish version of 
the VQLQ met the standards for good internal consist-
ency reliability with a Cronbach’s alpha of 0.97 in patients 
with vespid venom allergy. The internal consistency of 
VQLQ-T was very high with a Cronbach alpha of 0.97 
compared to the English version of 0.88. Consistent with 
results from other studies, the validity of VQLQ-T was 
found to be satisfactory as cross-sectionally, externally 
and longitudinally. Thus, our findings showed that the 
Turkish version of VQLQ-T had satisfactory psychomet-
ric properties as a measure of QoL in patients with both 
vespid and bee venom allergy. In addition, the question-
naire was well accepted by the patients, who were able 
to fill it out quickly (approximately 15 min) and without 
help.
To the best of our knowledge, established VQLQ 
instrument have not yet been validated for bee venom 
allergy. VQLQ-T is the first questionnaire to include 
Apis-allergic patients in its validation process. We 
excluded patients who were beekeepers from the analy-
ses, as in the first study conducted by Oude Elberink et al. 
(2002a). In their study, it is suggested that this instrument 
could be suitable for non-beekeepers who are allergic 
to honey bees. Since the allergy is an occupational dis-
ease in beekeepers, the approach to allergy in this group 
is different from the general population. As expected, 
beekeepers demonstrated better VQLQ scores than the 
non-beekeepers who were allergic to honey bees in our 
study. Despite this, the analysis of the internal consist-
ency of the VQLQ-T yielded a Cronbach α of 0.96, which 
can be considered to be excellent, and VQLQ-T showed 
a significant positive correlation with the EoO score in 
non-beekeepers. Therefore, it should be noted that this 
instrument is suitable for adult patients with bee venom 
allergy.
Items with lower correlations relating to check certain 
places for stinging insects (item 6) and watch out at work 
(item 10) may be probably due to less frequent expo-
sure to honey bees. However, increased fear level when 
a subject is stung by an insect (item 4) and in specific 
settings where stinging insects are likely occur (items 11 
and 12), concern about vigilance correlates to sting out-
come expectations to a comparable degree in vespid and 
bee venom allergic patients. From another point of view, 
items with low correlations related to gardening activities 
in vespid allergic patients may be due to low exposure 
to gardening activities in our population. On the other 
hand, in honey bee-venom allergic patients, correlations 
were found to be low relating to gardening, workplace 
activities and holidays. This may also be explained with 
rare exposure when compared to vespid allergic patients. 
However, correlations related to summertime activities 
were found to be significantly high in both vespid and 
honey bee allergic group.
It is well-known that venom immunotherapy (VIT) is 
very effective at preventing further anaphylactic reac-
tions after insect stings. Although Confino-Cohen et  al. 
showed that the QoL scores in venom allergic patients 
did not improve after VIT with their non-standardized 
questionnaire (Confino-Cohen et  al. 1999), studies 
using disease-specific instrument (VQLQ) have dem-
onstrated that VIT resulted in a significant improve-
ment in QoL scores of patients either who have treated 
with VIT or after tolerated sting challenge procedure 
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(Cichocka-Jarosz et al. 2012; Oude Elberink et al. 2002b; 
Fisher et  al. 2013). Also, this questionnaire was previ-
ously used to compare patients receiving VIT or adrena-
lin auto-injectors. Oude Elberink et  al. revealed that of 
every 3 patients treated with VIT, 2 patients experience 
an important improvement in their QoL after treatment 
(Oude Elberink et al. 2002b). In agreement with this data, 
we observed significantly lower VQLQ scores after VIT, 
consequently a high score on the VQLQ could reinforce 
starting VIT in patients with mild cutaneous systemic 
reactions (Oude Elberink et al. 2009). We believe that the 
use of the VQLQ-T in daily clinical practice could pro-
vide a useful tool for initial approaches to patients with 
venom allergy because those with a very poor QoL may 
need more efforts from the allergist to reassure them 
with regard to starting VIT (Findeis and Craig 2014).
It is already well-known that assessing the patient’s sub-
jective point of view via disease-specific questionnaire 
offers a more comprehensive description of the impact of 
the disease on patient’s everyday life (Smith et al. 1999). 
Having a validated instrument for patients with insect 
venom allergy will allow us for a greater understanding 
of the specific subjective experiences of venom allergy in 
our country.
Furthermore, the inclusion of patients living in differ-
ent geographic regions of the country, confirms that the 
questionnaire is suitable for the majority of the popula-
tion. The Turkish version of the VQLQ can therefore be 
used in advance research as well as in clinical routine 
in patients with vespid or bee venom allergy to assess 
somatopsychic stress and anxiety. It is also appropri-
ate for monitoring the influence on QoL of venom 
immunotherapy.
One of the major limitation of the study is that con-
struct validity has only been tested against the expecta-
tion of outcome questions. It would have been useful to 
examine convergent and divergent validity by looking at 
correlations with other validated scales.
In summary, here we present that the Turkish version 
of VQLQ enables the measurement of QoL in patients 
with vespid as well as bee venom allergy. We could repro-
duce the sufficient validity and reliability of the original 
version using the Turkish version of the VQLQ. Fur-
thermore, the responsiveness of this instrument demon-
strates the questionnaire’s ability to detect changes over 
time. Therefore it can be of use for further studies in our 
patients with insect venom allergy to determine both 
their psychological status and response to interventions.
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